Epigenetic alterations and anti-epigenetic therapy in myelofibrosis.

This publication has 19 references indexed in Scilit:

• Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy
  American Journal of Hematology, 2008
• Defining the steps that lead to cancer: Replicative telomere erosion, aneuploidy and an epigenetic maturation arrest of tissue stem cells
  Medical Hypotheses, 2008
• JAKandMPLmutations in myeloid malignancies
  Leukemia & Lymphoma, 2008
• Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
  Leukemia, 2007
• JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
  Leukemia, 2007
• Oncogenes in Myeloproliferative Disorders
  Cell Cycle, 2007
• Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
  New England Journal of Medicine, 2006
• Decitabine improves patient outcomes in myelodysplastic syndromes
  Cancer, 2006
• FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
  Blood, 2004
• Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
  Journal of Clinical Oncology, 2002